Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer

Future Medicinal Chemistry

Volumn 5, Issue 14, 2013, Pages 1661-1670

  Verma, Sharad K ^a   Knight, Steven D ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN; ANTINEOPLASTIC AGENT; DIPYRONE; E 7438; EI 1; EPZ 005687; EPZ 6438; GSK 126; GSK 343; HISTONE LYSINE METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE EZH2; HISTONE LYSINE METHYLTRANSFERASE EZH2 INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE INHIBITOR; MCPT 12; S ADENOSYLHOMOCYSTEINE; UNC 1999; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; B CELL LYMPHOMA; CANCER INHIBITION; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; EPIGENETICS; GENETIC TRANSCRIPTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; EPIGENESIS, GENETIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SMALL MOLECULE LIBRARIES;

EID: 84884567164     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.136     Document Type: Review

References (45)

1. American Cancer Society. Cancer Facts and Figures 2013. American Cancer Society Inc., Atlanta, GA, USA (2013).
2. Kouzarides T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128, 683-692 (2007).
4. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 9, 91-105 (2009).
5. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8, 355-367 (2007).
6. Copeland RA, Moyer MP, Richon VM. Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene 32, 939-946 (2013).
7. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8, 724-732 (2009).
8. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Epigenetics Mutat. Res. 647, 21-29 (2008).
9. Cheng X, Zhang X. Structural dynamics of protein lysine methylation and demethylation. Mutat. Res. 618, 102-115 (2007).
10. Dillon SC, Zhang X, Trievel RC. The SET-domain protein superfamily: Protein lysine methyltransferases. Genome Biol. 6, 227 (2005).
11. Varambally S, Cao Q, Ram-Shankar M et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-1699 (2008).
12. Varambally S, Dhanasekaran S, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
13. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003).
14. Wagener N et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10, 524 (2010).
15. Takawa M, Masuda K, Kunizaki M et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102, 1298-1305 (2011).
16. Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
17. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
18. Pasqualucci L, Trifonov V, Fabbri G et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830-837 (2011).
19. McCabe MT, Graves AP, Ganji G et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989-2994 (2012).
20. Sneeringer CJ, Scott MP, Kuntz KW et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980-20985 (2010).
21. Wigle TJ, Knutson SK, Jin, L et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett. 585, 3011-3014 (2011).
22. Yap DB, Chu J, Berg T et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451-2459 (2011).
23. Ernst T, Chase AJ, Score J et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722-726, (2010).
24. Richon VM, Johnston D, Sneeringer CJ et al. Chemogenetic analysis of human protein methyltransferases. Chem. Biol. Drug Des. 78, 199-210 (2011).
25. Zheng W, Ibanez G, Wu H et al. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. J. Am. Chem. Soc. 134, 18004-18014 (2012).
26. Miranda TB, Cortez C, Yoo C et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588 (2009).
27. Borchardt RT, Keller BT, Patel-Thombre U, Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. J. Biol. Chem. 259, 4353-4358 (1984).
28. Chiang PK Biological Effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol. Ther. 77, 115-134 (1998).
29. Diaz E, Machutta CA, Chen S et al. Development and validation of reagents and assays for EZH2 peptide and nucleosome high throughput screens. J. Biomol. Screen. 17, 1279-1292 (2012).
30. Verma SK, Tian X, LaFrance LV et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 3(12), 1091-1096 (2012).
31. McCabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
32. Qi W, Chan H, Teng L et al. Selective Inhibition of EZH2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109(52), 21360-21365 (2012).
33. Knutson S, Wigle TJ, Warholic NM et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012).
34. Keilhack H et al. Preclinical characterization of E7438, a potent, selective inhibitor of protein methyltransferase EZH2 with robust antitumor activity against EZH2 mutated non-hodgkin lymphoma xenografts in mice. Presented at: 54th American Society of Hematology Annual Meeting. Atlanta, GA, USA, 8-11 December 2012.
35. Knutson S, Warholic NM, Wigle TJ et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110, 7922-7927 (2013).
36. Konze KD, Ma A, Li F et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8(6), 1324-1334 (2013).
37. Simard JR, Plant M, Emkey R, Yu V. Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase. Assay Drug Dev. Tech. doi:10.1089/adt.481 (2013) (Epub ahead of print).
38. Valente S, Lepore I, Dell'Aversane C et al. Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie 94, 2308-2313 (2012).
39. Allan M, Manku S, Therrien E et al. N-benzyl-1-heteroaryl-3- (trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett. 19, 1218-1223 (2009).
40. Liu F, Chen X, Allali-Hassani A et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem. 52, 7950-7953 (2009).
41. Liu F, Chen X, Allali-Hassani A et al. Protein lysine methyltransferase G9a inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J. Med. Chem. 53, 5844-5857 (2010).
42. Daigle SR, Olhava EJ Therkelsen CA et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011).
43. Yao Y, Chen P, Diao J et al. Selective inhibitors of histone methyltransferase DOT1L: Design, synthesis, and crystallographic studies. J. Am. Chem. Soc. 133, 16746-16749 (2011).
44. Ferguson AD, Larsen NA, Howard T et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure 19, 1262-1273 (2011).
45. Vedadi M, Barsyte-Lovejoy D, Liu F et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 7, 566-574 (2011).